Skip to main content
SSII logo

SSII · SS Innovations International, Inc.

Track SSII — free
$1.31 +0.03 (+1.95%)
Market Cap
$256.74M
Shares
200.58M
Volume · Nov 20 18.86K Avg daily vol (3M) 85.57K

Price & Indicators

 

Key stats

Close
$1.28
Open
$1.31
Day range
$1.18–1.35
52-week closing range
$1.28–6.73
Average volume, 30 days
113K
Short interest
64K · 0.0% of shares · 1.1 days
Short volume, last session
72%
Last earnings
Oct 28, 2025
Latest filing
10-Q · Nov 16
Price history
Aug 2024 to Nov 2026

Latest documents

2026
Nov 19
Current report 8-K
World's First Dual-Console Beating-Heart TECAB Surgery Using Five Robotic Arms

SS Innovations' SSi Mantra system completed the world's first dual-console, beating-heart TECAB surgery using all five arms at Medanta Hospital in Gurugram, India. Dr. Nitin Kumar Rajput and Dr. Lalit Malik performed the procedure under Dr. Sudhir Srivastava's guidance.

Other events
2 source passages
a team of surgeons successfully completed the world’s first dual-console, beating-heart Totally Endoscopic Coronary Artery Bypass (“TECAB”) surgery utilizing all five arms of the Company’s SSi Mantra surgical robotic system (the “SSi Mantra”) at Medanta - The Medicity Hospital (“Medanta Hospital”) in Gurugram, India. Dr. Nitin Kumar Rajput of Medanta Hospital and Dr. Lalit Malik of Manipal Hospital, Jaipur, successfully performed the beating-heart TECAB procedure using two separate consoles and the SSi Mantra, under the guidance of Dr. Sudhir Srivastava, the Company’s Chairman of Open the document at this passage
Nov 17
Current report 8-K
Chairman Buys 100,000 Shares Paid With $300,000 Owed Compensation

SS Innovations International's Chairman and CEO Dr. Sudhir Srivastava, through Sushruta Pvt. Ltd., bought 100,000 common shares at $3.00 per share on November 17, 2026, paying $300,000 by exchanging accrued unpaid compensation owed to him.

Unregistered sale of equity, Director or officer change, or executive pay
2 source passages
On November 17, 2026, Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer, through Sushruta Pvt. Ltd., his holding company, purchased 100,000 shares of our common stock for an aggregate purchase price of $300,000 ($3.00 per share). The purchase price was paid by exchanging the Shares for $300,000 owed by the Company to Dr. Srivastava in accrued but unpaid compensation. Open the document at this passage
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue falls to $6,331,061; net loss widens to $5,749,389

SS Innovations reported three-month revenue of $6,331,061, down from $12,829,349 a year earlier, as net loss widened to $5,749,389 from $3,717,964. Research and development expense rose to $2,500,826 on regulatory and clinical trial costs.

Revenue $6.33M ▼ 50.7% Net loss $5.75M Diluted EPS -$0.03
Read from the MD&A section
5 source passages
For the three months ended September 30, 2026, we had revenues of $6,331,061 (comprised of $4,720,096 of system sales compared to revenues of $12,829,349 We incurred net loss of $5,749,389 for the three months ended September 30, 2026, as compared to a net loss of $3,717,964 Research and development expenses for the three months ended September 30, 2026, were $2,500,826, as compared to $786,319 The increase was primarily attributable to higher expenditures incurred in connection with clinical trials and related regulatory activities Open the document at this passage
Nov 13
Current report 8-K Events of Nov 6
Gary G. Lo named CFO; Vishwajyoti P. Srivastava named President

SS Innovations International, Inc. appointed Gary G. Lo CFO and Vishwajyoti P. Srivastava President, effective November 6, 2026. Srivastava will lead U.S. and European regulatory efforts for SSi Mantra; Lo’s annual base salary is $400,000.

Director or officer change, or executive pay Read from the first part of this long document
4 source passages
Effective November 6, 2026, Gary G. Lo joined the Company as its new Chief Financial Officer. Effective November 6, 2026, the Company appointed Dr. Vishwajyoti P. Srivastava, M.D., who had been serving as the Company’s Chief Executive Officer – Asia Pacific, as President of the Company. As President, Dr. Srivastava will oversee and coordinate the Company’s efforts to obtain regulatory approval to market its SSi Mantra robotic surgical system in the United States and the European Union. The Employment Agreement provides for annual base compensation of $400,000. Open the document at this passage
Oct 26
Current report 8-K
SSi Mantra Shows Telesurgery Capabilities at October 2026 Conferences

SS Innovations showcased its SSi Mantra system in successful October 2026 telesurgeries at EACTS in Barcelona and SRS India in New Delhi. As of October 23, 2026, 205 telesurgeries have been performed with the SSi Mantra system.

Other events
2 source passages
On October 26, 2026, SSi issued a press release announcing that the Company’s SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console (the “SSi MantrAsana”) were showcased in successful telesurgeries performed in October 2026 during the European Association for Cardio-Thoracic Surgery (“EACTS”) Annual Meeting in Barcelona, Spain and the Society of Robotic Surgery India (“SRS India”) Conference in New Delhi, India. As of October 23, 2026, a total of 205 telesurgeries, including intricate cardiac procedures, have been performed with the SSi Mantra surgical robotic system. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$45.91M
Trailing 12 months
Net income (TTM)
−$14.46M
Trailing 12 months
Revenue growth YoY
-50.7%
Year over year
Operating margin
-27.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$6.86M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.3%
Year over year · more shares
Price change (1Y)
-80.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −65%
below
Price vs 50-day avg −48%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −46%
trailing
6-month return −68%
trailing
YTD return −77%
this year
Relative strength −62%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+9% holders QoQ · +6 funds added
Insider flow Accumulating
Net +$200.0K over 90 days · 50% sells
Short interest Falling
0.03% of shares out · ▼ -7.6% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
25 holders — mid 1-yr range
Squeeze score 25
low risk · 0–100
Fundamentals
Strong
Revenue growth +106%
Y/Y
Gross margin 46%
expanding
EPS growth +45%
Y/Y
Free cash flow $-22.2M
Balance sheet $8.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 91%
annualized · 1-yr
Max drawdown −81%
past year
ATR 23.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−65% Bearish
Price vs 50-day avg
−48% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+9% holders QoQ · +6 funds added
Insider flow Accumulating
Net +$200.0K over 90 days · 50% sells
Short interest Falling
0.03% of shares out · ▼ -7.6% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
25 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $7
vs 200-day avg -65% vs 50-day avg -48%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cumulative cardiac procedures 637 As of June 30, 2026 —
Cumulative pediatric surgeries 222 As of June 30, 2026 —
Cumulative surgeries 12,272 As of June 30, 2026 —
Cumulative telesurgeries 175 As of June 30, 2026 —
SSi Mantra cumulative installed base 224 As of June 30, 2026 —
SSi Mantra surgeries 4,387 H1 2026 —
SSi Mantra surgical robotic system installations 56 H1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SSII
SS Innovations International, Inc.
this stock
$256.74M -77.5% +105.7% — 0.0%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
25
% held
0.8%
Net QoQ
+26.7K sh
Top holder
Hood River Capital Manage…
Held Float
View
Held by Funds
Fund positions
8
View
Short & Settlement
Short Interest Falling
Shares short
64.3K
Days to cover
1.1d
Change
-5.3K sh
View
Short Volume
Short vol %
72%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
412
Value
$981
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
46.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$200.0K
Buyers / Sellers
1 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$42.5M
Net income (FY)
$-12.1M
EPS diluted
$-0.06
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 19, 2026
This year
37

SS Innovations' SSi Mantra system completed the world's first dual-console, beating-heart TECAB surgery using all five arms at Medanta Hospital in Gurugram, India. Dr. Nitin Kumar Rajput and Dr. Lalit Malik performed the procedure under Dr. Sudhir Srivastava's guidance.

View
Exempt Offerings
Offering
$18.6M
Filed
Mar 19, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2025
View
Investor Relations
Latest news
SS Innovations Announces World’s…
Published
Nov 19, 2026
View

Performance

5D 20D 120D MTD YTD
SSII -3.0% -46.0% -67.5% -45.5% -77.5%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +2.4% -39.7% -61.9% -40.3% -82.4%
Key facts CIK 1676163 CUSIP 05453U203 13F (30d) 24 filings 23 filers Visit website Investor relations